Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
ImmunityBio (IBRX) Stock Price & Analysis
921 Followers
IBRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.25 - $10.53
Previous Close$8.63
Volume3.49M
Average Volume (3M)7.44M
Market Cap
$6.05B
Enterprise Value$6.58B
Total Cash (Recent Filing)$266.46M
Total Debt (Recent Filing)$882.14M
Price to Earnings (P/E)-8.2
Beta1.51
Next Earnings
Aug 09, 2023EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding691,567,961
10 Day Avg. Volume9,266,432
30 Day Avg. Volume7,438,751
Standard Deviation0.35
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)-9.06
Price to Sales (P/S)42936.91
Price to Cash Flow (P/CF)-11.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.59K
Enterprise Value/Gross Profit10.59K
Enterprise Value/Ebitda-21.92
Forecast
1Y Price Target
$6.00Price Target Upside-31.43% Downside
Rating ConsensusHold
Number of Analyst Covering1
ImmunityBio News
Ownership Overview
52.18% Insiders
2.51% Mutual Funds
5.53% Other Institutional Investors
39.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $1.25 and its highest was $10.53 in the past 12 months.
What is ImmunityBio’s market cap?
Currently, no data Available
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Aug 09, 2023 which is 279 days ago.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on May 11, 2023. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.27.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Overvalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -$0.24.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 691,567,930 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.215%.
Which hedge fund is a major shareholder of ImmunityBio?
Among the largest hedge funds holding ImmunityBio’s share is Harbourvest Partners Llc. It holds ImmunityBio’s shares valued at 2M.
---
ImmunityBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.00 (-31.43% Downside)
$6.00 (-31.43% Downside)
Blogger Sentiment
Bullish
IBRX Sentiment 81%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 10.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 27.3%
Last 30 Days ▲ 27.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
278.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.68%
Trailing 12-Months
Company Description
ImmunityBio
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
---
IBRX Stock 12 Month Forecast
Average Price Target
$6.00
▼(-31.43% Downside)
Technical Analysis
---